NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Ensysce Biosciences, Inc. ENSC
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.1M
▼ 2.8% vs FY2024
EPS · FY25
$-3.98
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-294.0%
Net margin · FY25
-200.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.1M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 201 cents on every revenue dollar this year.
Per share
USD -3.98
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-294.0%
Return on equity, FY2025
ROE
Operating margin-202.1%
Net margin-200.8%
Return on assets-156.0%
Each USD of equity lost 294 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+26.2%
+5.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.5M
total assets, end of FY2025
Total assetsUSD 7.5M
EquityUSD 3.2M
CashUSD 4.3M
Gross debtUSD 306,708.00
Net debtUSD -4.0M
Current ratio1.59×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−3.98
−11.45
−70.40
−139.42
−1.48
0.00
−0.63
−0.21
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−294.0
−471.8
·
·
·
·
−21.3
41.1
Shares out B
0.00
0.00
0.00
0.00
0.00
0.02
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed